PCI Pharma Services

PCI Pharma Services delivers integrated end-to-end drug development, manufacturing, packaging, storage, distribution and logistics solutions to pharmaceutical and biopharmaceutical companies globally. It specializes in complex injectable biologics and small molecule drug-device combinations. The company operates more than thirty GMP facilities worldwide with over fifty years of experience in healthcare services.[1][2][3][5]

As a service provider/CDMO/CMO rather than a product innovator or biotech developer with its own pipeline or clinical results.

No proprietary clinical pipeline—supports client programs at all stages.

Over ninety successful product launches per year for clients.[1]

Recent expansions include new Centers of Excellence focused on biologics in Rockford IL and Bridgewater MA to support growing demand for injectable therapies including those targeting diabetes/obesity (GLP‑1s), oncology/cancer care, autoimmune diseases.[5][6]

Investments have been made into aseptic fill-finish capabilities and high-volume lyophilization technology at sites such as Bedford NH.[7]

Employs over four thousand people globally across seven countries.

Notable recent investments include $100M+ into Bedford NH facility expansion,[7] $150M into Rockford IL biologics center,[8] new Center of Excellence openings in New England/Midwest US regions.

Parent company/private equity owner not explicitly named but Mubadala lists it among direct investments; previously associated with Thomas H. Lee Partners ("THL"). [2][4]